Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent…
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of Entyvio® Pens for subcutaneous (SC) injection 108 mg / Syringes…
Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1 NATALEE is the first and only positive Phase III study…
Across two clinical trials 82% overall response and 35% complete response ratewere observed in Chinese patients using Calquence AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been…
Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA…
Dupixent®demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial The primary and all key secondary endpoints were met in a Phase 3…
New Facility Will Strengthen Takeda’s Manufacturing and Supply Capabilities to Meet Growing Patient Need for Plasma-Derived Therapies (PDTs) in Japan and Globally Takeda’s Largest Ever Investment in Manufacturing Capacity Expansion…
At the Annual General Meeting, Helge Lund, Chair of the Board of Directors communicated:“We are very pleased with the performance of Novo Nordisk in 2022, where we continued to make…
Results of the M19-130 (SLEek) Phase 2 trial of upadacitinib given alone or as a combination therapy (ABBV-599) met the primary endpoint of systemic lupus erythematosus (SLE) Responder Index (SRI-4)…
AbbVie (NYSE: ABBV) today announced positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab (SKYRIZI®,1200 mg intravenous [IV], at weeks 0, 4 and 8) met the primary…
Data shows investigational zolbetuximab plus CAPOX reduced risk of progression or death by 31.3% vs CAPOX alone Study evaluated patients with Claudin 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric…
Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel The Elecsys Amyloid Plasma Panel has demonstrated clinical performance and is currently undergoing additional investigation to ensure clinical validation…